Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rosuvastatin Calcium

FDA-approved product (tablet, oral), marketed as Crestor, Ezallor Sprinkle, Rosuvastatin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Rosuvastatin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atherosclerosis
  • Cardiovascular disease
  • Coronary artery disease
  • Familial hypercholesterolemia
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hyperlipoproteinemia type 3

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Hmg coa reductase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rosuvastatin Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rosuvastatin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

    NCT02662894 · start 2019-10

    Registered record
    Registry ID
    NCT02662894
    Conditions
    Hypertension; Dyslipidemia
    Interventions
    Valsartan 160mg + Rosuvastatin 20mg; Valsartan 320mg + Rosuvastatin 20mg; Diovan® 160mg + Crestor® 20mg; Diovan® 320mg + Crestor® 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-10
    Completion
    2020-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia
    InterventionValsartan 160mg + Rosuvastatin 20mg; Valsartan 320mg + Rosuvastatin 20mg; Diovan® 160mg + Crestor® 20mg; Diovan® 320mg + Crestor® 20mg
    PhasePhase 3
    Registry statusWithdrawn

  • Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

    NCT03907423 · start 2019-04-01

    Registered record
    Registry ID
    NCT03907423
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Rosuvastatin10 mg tablet; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2021-01-31
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionRosuvastatin10 mg tablet; Placebo Oral Tablet
    PhaseNot applicable
    Registry statusCompleted

  • The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.

    NCT03690778 · start 2018-10-04

    Registered record
    Registry ID
    NCT03690778
    Conditions
    Diabetes; Hyperlipidemias
    Interventions
    "Metformin" and "Rosuvastatin" seperately; JLP-1310
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-04
    Completion
    2019-02-01
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Hyperlipidemias
    Intervention"Metformin" and "Rosuvastatin" seperately; JLP-1310
    PhasePhase 1
    Registry statusCompleted

  • Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

    NCT03874260 · start 2018-07-25

    Registered record
    Registry ID
    NCT03874260
    Conditions
    Dyslipidemias
    Interventions
    Fenofibrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-07-25
    Completion
    2020-03-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias
    InterventionFenofibrate
    PhasePhase 4
    Registry statusUnknown

  • Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

    NCT03801733 · start 2018-06-17

    Registered record
    Registry ID
    NCT03801733
    Conditions
    Drug Interaction Potentiation
    Interventions
    Vadadustat; Simvastatin; Rosuvastatin; Atorvastatin; Pravastatin; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-17
    Completion
    2018-11-24
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction Potentiation
    InterventionVadadustat; Simvastatin; Rosuvastatin; Atorvastatin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802

    NCT03532854 · start 2018-05-28

    Registered record
    Registry ID
    NCT03532854
    Conditions
    Healthy Male Volunteers
    Interventions
    Valsartan; Ezetimibe/Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-28
    Completion
    2019-01-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Male Volunteers
    InterventionValsartan; Ezetimibe/Rosuvastatin
    PhasePhase 1
    Registry statusCompleted

  • Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

    NCT03772262 · start 2018-04-05

    Registered record
    Registry ID
    NCT03772262
    Conditions
    Interaction Drug Food
    Interventions
    goldenseal; Metformin; Furosemide; Midazolam oral solution; Rosuvastatin Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-04-05
    Completion
    2019-03-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInteraction Drug Food
    Interventiongoldenseal; Metformin; Furosemide; Midazolam oral solution +1 more
    PhaseEarly phase 1
    Registry statusCompleted

  • Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

    NCT03175835 · start 2017-05-08

    Registered record
    Registry ID
    NCT03175835
    Conditions
    Dyslipidemias
    Interventions
    Rosuvastatin 20 mg; CKD-519 200 mg; Rosuvastatin 20 mg & CKD-519 200 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-08
    Completion
    2017-06-19
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyslipidemias
    InterventionRosuvastatin 20 mg; CKD-519 200 mg; Rosuvastatin 20 mg & CKD-519 200 mg
    PhasePhase 1
    Registry statusCompleted

  • Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate

    NCT02671097 · start 2016-02

    Registered record
    Registry ID
    NCT02671097
    Conditions
    Healthy Volunteers; Pharmacokinetics; Drug Interaction
    Interventions
    Rosuvastatin; BAY1841788 (ODM-201)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers; Pharmacokinetics; Drug Interaction
    InterventionRosuvastatin; BAY1841788 (ODM-201)
    PhasePhase 1
    Registry statusCompleted

  • Effect of Rosuvastatin Therapy on HDL2 Level

    NCT02593487 · start 2015-11

    Registered record
    Registry ID
    NCT02593487
    Conditions
    Hyperlipemia; Coronary Heart Disease
    Interventions
    Rosuvastatin 10mg/d group; Rosuvastatin 20mg/d group
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2017-06
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperlipemia; Coronary Heart Disease
    InterventionRosuvastatin 10mg/d group; Rosuvastatin 20mg/d group
    PhasePhase 4
    Registry statusUnknown

  • A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)

    NCT02477514 · start 2015-06

    Registered record
    Registry ID
    NCT02477514
    Conditions
    Skin Diseases, Bacterial
    Interventions
    midazolam; rosuvastatin; tedizolid phosphate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-08
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Bacterial
    Interventionmidazolam; rosuvastatin; tedizolid phosphate
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

    NCT02289963 · start 2015-01

    Registered record
    Registry ID
    NCT02289963
    Conditions
    Hypercholesterolemia
    Interventions
    Placebo (for Alirocumab); Alirocumab; Lipid-Modifying Therapy (LMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-04
    Enrolment
    199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypercholesterolemia
    InterventionPlacebo (for Alirocumab); Alirocumab; Lipid-Modifying Therapy (LMT)
    PhasePhase 3
    Registry statusCompleted

  • Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment

    NCT02645227 · start 2015-01

    Registered record
    Registry ID
    NCT02645227
    Conditions
    Chronic Periodontitis
    Interventions
    Open flap debridement (OFD); OFD with Platelet rich fibrin (PRF); OFD with PRF and 1.2% Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Periodontitis
    InterventionOpen flap debridement (OFD); OFD with Platelet rich fibrin (PRF); OFD with PRF and 1.2% Rosuvastatin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

    NCT02106767 · start 2014-11

    Registered record
    Registry ID
    NCT02106767
    Conditions
    Healthy
    Interventions
    Rosuvastatin; Rosuvastatin plus rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    2016-08-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionRosuvastatin; Rosuvastatin plus rifampin
    PhasePhase 1
    Registry statusCompleted

  • Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

    NCT02008786 · start 2014-06

    Registered record
    Registry ID
    NCT02008786
    Conditions
    Coronary Artery Dissection, Spontaneous
    Interventions
    ramipril; rosuvastatin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2014-06
    Completion
    2019-09-13
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Dissection, Spontaneous
    Interventionramipril; rosuvastatin; placebo
    PhasePhase 4
    Registry statusTerminated